Skip to content
Peptigraph home
Shop Peptides50% off*

How does tesamorelin target visceral fat?

In abdominally obese adults with reduced growth hormone secretion, tesamorelin lowered visceral fat selectively, with no significant change in subcutaneous fat. The trial reports the pattern; it does not prove why fat depots respond differently.

GHRH analogUpdated

Short answer

In abdominally obese adults with reduced growth hormone secretion, tesamorelin lowered visceral fat selectively, with no significant change in subcutaneous fat. The trial reports the pattern; it does not prove why fat depots respond differently.[1]

Tesamorelin is an analog of growth hormone-releasing hormone, so it acts by prompting the body's own growth hormone release rather than supplying growth hormone.[1]

The trial's IGF-I level, a marker downstream of growth hormone, rose on tesamorelin and was flat on placebo, consistent with that route.[1]

Which fat changes

In a dose-ranging trial in HIV-infected patients with abdominal fat, trunk fat fell against placebo with no significant change in limb fat.[2]

The effect depends on staying on treatment: in the long-term trial visceral fat came back after tesamorelin was stopped.[3]

Patients whose visceral fat fell by at least 8% on tesamorelin had better triglycerides and adiponectin than non-responders, linking the fat loss itself to the metabolic changes.[4]

More questions on Tesamorelin

Can tesamorelin cause weight gain?Can women take tesamorelin?Does tesamorelin cause cancer?Does tesamorelin cause water retention?Does tesamorelin help build muscle?Does tesamorelin show up on a drug test?

More on Tesamorelin

How it worksTarget, mechanism and how long it acts, from the label or studies.Tesamorelin overview

Sources

  1. 1Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  2. 2A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
  3. 3Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  4. 4Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012PMID 22495074Accessed 2 Oct 2026

Found an error? Report a correction.